{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:38:26Z","timestamp":1794335906381,"version":"4.9.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031365","name":"Oslo universitetssykehus HF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010586","name":"Haukeland\u00a0Universitetssjukehus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128290","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:36:48Z","timestamp":1769917008000},"page":"128290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1\/2 open-label clinical trial"],"prefix":"10.1016","volume":"75","author":[{"given":"Camilla","family":"T\u00f8ndel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synne","family":"Jenum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Tonby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Egeland","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Jane","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese Bredholt","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Gail","family":"Skeie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barb","family":"Banbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe J\u00f8ntvedt","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Pourpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild S\u00f8rum","family":"Leikfoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedda","family":"Wold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Torhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokouh","family":"Makvandi-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Edo-Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Schjetne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnete Brunsvik","family":"Fredriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnstein","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Ma","family":"Dyrhol-Riise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128290_bb0005","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.128290_bb0010","author":"Link-Gelles"},{"key":"10.1016\/j.vaccine.2026.128290_bb0015","author":"ECDC"},{"key":"10.1016\/j.vaccine.2026.128290_bb0020","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128290_bb0025","author":"CDC"},{"key":"10.1016\/j.vaccine.2026.128290_bb0030","author":"EMA"},{"key":"10.1016\/j.vaccine.2026.128290_bb0035","article-title":"Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023","volume":"29","author":"Werkhoven","year":"2024","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2026.128290_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMp2215780","article-title":"Bivalent Covid-19 vaccines \u2014 a cautionary tale","volume":"388","author":"Offit","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128290_bb0045","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","article-title":"Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study","volume":"23","author":"Chemaitelly","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128290_bb0050","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1056\/NEJMp2307867","article-title":"Project NextGen \u2014 defeating SARS-CoV-2 and preparing for the next pandemic","volume":"389","author":"Becerra","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128290_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101828","article-title":"T cell control of SARS-CoV-2: when, which, and where?","volume":"70","author":"Diniz","year":"2023","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0065","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128290_bb0070","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2666-5247(23)00255-0","article-title":"Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study","volume":"5","author":"Guo","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128290_bb0075","first-page":"346","article-title":"SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity","volume":"87","author":"Mohn","year":"2023","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.128290_bb0080","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1038\/s41467-021-24377-1","article-title":"SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128290_bb0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.vaccine.2010.10.057","article-title":"Human chemokine MIP1\u03b1 increases efficiency of targeted DNA fusion vaccines","volume":"29","author":"Ruffini","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128290_bb0090","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2006-06-032938","article-title":"Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences","volume":"110","author":"Fredriksen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128290_bb0095","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","article-title":"A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase I\/IIa trial","volume":"28","author":"Hillemanns","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2026.128290_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010827","article-title":"Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study","volume":"13","author":"Hillemanns","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.vaccine.2026.128290_bb0105","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.210.Supp.159.03","article-title":"Antigen presenting cell targeted T cell DNA vaccine inducing strong and specific cellular responses across multiple T cell epitopes of SARS-COV-2","volume":"210","author":"Norheim","year":"2023","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141561","article-title":"Multiplex identification of antigen-specific T cell receptors using a combination of immune assays and immune receptor sequencing","volume":"10","author":"Klinger","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128290_bb0115","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","volume":"310","author":"WMA","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128290_bb0120","author":"C. for E. P. I. Safety Platform for Emergency Vaccines (SPEAC)"},{"key":"10.1016\/j.vaccine.2026.128290_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/erv.10.169","article-title":"ELISpot for measuring human immune responses to vaccines","volume":"10","author":"Slota","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128290_bb0130","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/cyto.a.23724","article-title":"Comprehensive phenotyping of T cells using flow cytometry","volume":"95","author":"Mousset","year":"2019","journal-title":"Cytom Part A"},{"key":"10.1016\/j.vaccine.2026.128290_bb0135","article-title":"A large-scale database of T-cell receptor beta (TCR\u03b2) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2","author":"Nolan","year":"2020","journal-title":"Res Sq"},{"key":"10.1016\/j.vaccine.2026.128290_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1488860","article-title":"Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels","volume":"15","author":"Snyder","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0145","article-title":"Safety and immunogenicity of an Andes virus DNA vaccine by needle-free injection: a randomized, controlled phase 1 study","author":"Paulsen","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128290_bb0150","series-title":"World Health Organization: Guidelines on the Quality, Safety and Efficacy of Plasmid DNA Vaccines, Annex 2, TRS No 1028","first-page":"54","author":"WHO","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128290_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113889","article-title":"The role of SARS-CoV-2 accessory proteins in immune evasion","volume":"156","author":"Zandi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2026.128290_bb0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128290_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg5669","article-title":"CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients","volume":"6","author":"Mallajosyula","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128290_bb0175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00251-023-01294-9","article-title":"Role of T cells in severe COVID-19 disease, protection, and long term immunity","volume":"75","author":"Hermens","year":"2023","journal-title":"Immunogenetics"},{"key":"10.1016\/j.vaccine.2026.128290_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128290_bb0185","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0190","author":"Mathieu"},{"key":"10.1016\/j.vaccine.2026.128290_bb0195","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize omicron","volume":"1\u20135","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128290_bb0200","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.vaccine.2026.128290_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869990","article-title":"Long-lasting T cell responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 convalescent patients","volume":"13","author":"Hurme","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0210","author":"FHI"},{"key":"10.1016\/j.vaccine.2026.128290_bb0215","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128290_bb0220","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200592119","article-title":"Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles","volume":"119","author":"Syed","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128290_bb0225","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/infdis\/jiad353","article-title":"SARS-CoV-2 hybrid immunity: the best of both worlds","volume":"228","author":"Lasrado","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128290_bb0230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41590-023-01692-x","article-title":"Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19","volume":"25","author":"Ford","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0235","series-title":"Risk of Post-COVID Condition Under Hybrid Immunity - Results from the German National Cohort (NAKO)","author":"Mikolajczyk","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128290_bb0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garc\u00eda-Su\u00e1rez","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0245","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/ajt.16708","article-title":"T cell\u2013mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19","volume":"21","author":"Fern\u00e1ndez-Ruiz","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2026.128290_bb0250","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-21-0191","article-title":"Preexisting and post\u2013COVID-19 immune responses to SARS-CoV-2 in patients with cancer","volume":"11","author":"Bilich","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.vaccine.2026.128290_bb0255","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/acn3.52081","article-title":"Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination","volume":"11","author":"Kister","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.vaccine.2026.128290_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104922","article-title":"Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study","volume":"99","author":"Miauton","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128290_bb0265","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.vaccine.2026.128290_bb0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2023.11.009","article-title":"Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults","volume":"139","author":"Tandler","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128290_bb0275","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2024013344","article-title":"Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19","volume":"8","author":"Grosso","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2026.128290_bb0280","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41591-023-02480-8","article-title":"SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1\/2 trial","volume":"29","author":"Papadopoulou","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128290_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00769-2","article-title":"Targeting the SARS-CoV-2 reservoir in long COVID","author":"Proal","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128290_bb0290","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2","volume":"601","author":"Swadling","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128290_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2022.02.003","article-title":"Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status","author":"Yu","year":"2022","journal-title":"Cell Host Microbe"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:49:52Z","timestamp":1772552992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"alternative-id":["S0264410X26000988"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128290","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1\/2 open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128290"}}